Maryland reaches $340 million Conowingo Dam agreement with Constellation
Investing.com - Jefferies has reiterated its Hold rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) with a price target of $10.00. The company, which has seen its stock drop nearly 15% in the past week according to InvestingPro data, maintains strong fundamentals with an 80% gross margin and healthy balance sheet metrics.
The reiteration follows controversy surrounding a blog post by the FDA Center for Drug Evaluation and Research (CDER) director that questioned the clinical benefit of Aurinia’s lead drug Lupkynis/voclosporin for lupus nephritis (LN).
According to Jefferies, the FDA official stated the drug lacks evidence on outcomes, a position the research firm disagrees with based on strong clinical evidence from Aurinia’s Phase III data.
The FDA director subsequently deleted the post and clarified that the comments represented his personal views rather than official positions of the FDA and Department of Health and Human Services (HHS).
Jefferies indicated that while it maintains a Hold rating on Aurinia stock, it believes the market selloff following the FDA director’s comments was unwarranted. InvestingPro analysis suggests the stock is currently trading below its Fair Value, with analysts projecting earnings growth for the upcoming year.
In other recent news, Aurinia Pharmaceuticals reported a strong performance for the second quarter of 2025. The company achieved earnings per share (EPS) of $0.16, surpassing the market forecast of $0.14, which represents a 14.29% surprise. Revenue for the quarter reached $70 million, exceeding the anticipated $64.27 million, resulting in an 8.92% surprise. These results highlight the company’s continued growth, as both earnings and revenue outpaced expectations. The positive earnings announcement reflects investor optimism in the company’s financial health. While the stock price experienced a surge following the announcement, the focus remains on the solid financial results achieved by Aurinia Pharmaceuticals. These developments are crucial for investors monitoring the company’s performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.